Cargando…
1639P Impact of COVID-19 on ongoing oncological and hematological treatment strategy
Autores principales: | Bayle, A., Ouali, K., Colomba, E., Ibrahimi, N., Foulon, S., Gachot, B., Willekens, C., Stoclin, A., Merad, M., Griscelli, F., Sun, R., Ammari, S., Michot, J-M., André, F., Scotté, F., Besse, B., Soria, J-C., Barlesi, F., Albiges, L., Pommeret, F. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
European Society for Medical Oncology. Published by Elsevier Ltd.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8454312/ http://dx.doi.org/10.1016/j.annonc.2021.08.1632 |
Ejemplares similares
-
Severe COVID-19 in patients with hematological cancers presenting with viremia
por: Michot, J.M., et al.
Publicado: (2021) -
1688P Outcome of older cancer patients infected with COVID-19 at Gustave Roussy Cancer Center
por: Hauchecorne, M., et al.
Publicado: (2020) -
Tocilizumab, an anti-IL-6 receptor antibody, to treat COVID-19-related respiratory failure: a case report
por: Michot, J.-M., et al.
Publicado: (2020) -
Bamlanivimab + etesevimab therapy induces SARS-CoV-2 immune escape mutations and secondary clinical deterioration in COVID-19 patients with B-cell malignancies
por: Pommeret, F., et al.
Publicado: (2021) -
Systematic Screening of COVID-19 Disease Based on Chest CT and RT-PCR for Cancer Patients Undergoing Radiation Therapy in a Coronavirus French Hotspot
por: Sun, Roger, et al.
Publicado: (2021)